Interaction Profile of Moxifloxacin

Stass, H.; Kubitza, D.
December 1999
Drugs;Dec1999 Supplement 2, Vol. 58 Issue 6, p235
Academic Journal
Investigates the influence of probenecid on the elimination of moxifloxacin. Methods; Results.


Related Articles

  • Moxifloxacin.  // Reactions Weekly;Sep2015, Vol. 1568 Issue 1, p202 

    The article presents a case study of a 78-year-old male patient who developed acute confusional syndrome during moxifloxacin treatment.

  • Comparative In Vitro and In Vivo Activity of the C-8 Methoxy Quinolone Moxifloxacin and the C-8 Chlorine Quinolone BAY γ 3118. Dalhoff, Axel // Clinical Infectious Diseases;3/15/2001 Supplement 1, Vol. 32, pS16 

    The C-8 methoxy quinolone moxifloxacin is highly bactericidal against wild-type and first-step gyrase-and topoisomerase IV-resistant mutants. This finding led to the hypothesis that the C-8 methoxy group may lower the propensity for resistance development compared with quinolones possessing...

  • Single- and multiple-dose pharmacokinetics of intravenous moxifloxacin in patients with severe hepatic impairment. Jürgen Barth; Doris Jäger; Ralf Mundkowski; Bernd Drewelow; Tobias Welte; Olaf Burkhardt // Journal of Antimicrobial Chemotherapy (JAC);Sep2008, Vol. 62 Issue 3, p575 

    : Objectives The aim of this study was to investigate the single- and multiple-dose pharmacokinetics (PK) of moxifloxacin and its penetration into ascitic fluid in patients with severe liver insufficiency (Child–Pugh class C). : Patients and methods In a single-centre, prospective,...

  • Factors compromising the activity of moxifloxacin against intracellular Staphylococcus aureus. Hoang Anh Nguyen; Jean Grellet; Véronique Dubois; Marie-Claude Saux; Claudine Quentin // Journal of Antimicrobial Chemotherapy (JAC);Mar2007, Vol. 59 Issue 4, p755 

    Objectives The aim of this study was to determine the intracellular activity of moxifloxacin against a reference strain and a clinical strain and to study the factors compromising the intracellular activity of moxifloxacin. Methods The bactericidal activity of...

  • Variation in the mutation frequency determining quinolone resistance in Chlamydia trachomatis serovars L2 and D. Jan Rupp; Werner Solbach; Jens Gieffers // Journal of Antimicrobial Chemotherapy (JAC);Jan2008, Vol. 61 Issue 1, p91 

    : Objectives Quinolone resistance of chlamydiae is supposed to be extremely rare. To assess the risk for the emergence of chlamydial quinolone resistance, we analysed the occurrence of resistant mutants in a quantitative perspective. : Methods Infectious elementary bodies of Chlamydia...

  • In vitro interactions of LytA, the major pneumococcal autolysin, with two bacteriophage lytic enzymes (Cpl-1 and Pal), cefotaxime and moxifloxacin against antibiotic-susceptible and -resistant Streptococcus pneumoniae strains. Violeta Rodríguez-Cerrato; Pedro García; Gema del Prado; Ernesto García; Matilde Gracia; Lorena Huelves; Carmen Ponte; Rubens López; Francisco Soriano // Journal of Antimicrobial Chemotherapy (JAC);Nov2007, Vol. 60 Issue 5, p1159 

    Objectives In an innovative therapeutic exploitation against antibiotic-resistant Streptococcus pneumoniae, here we have evaluated the in vitro activity of a purified bacterially-encoded cell wall lytic enzyme, LytA (the major pneumococcal autolysin), and compared it with those of Cpl-1 and Pal...

  • Moxifloxacin for Odontogenic Infection.  // Infectious Disease Alert;Nov2011, Vol. 31 Issue 2, p20 

    Outpatients with a diagnosis of either dentoalveolar or periodontal abscess or a diagnosis of gingival inflammatory infiltrates were randomized to receive either moxiloxacin 400 mg daily or clindamycin 300 mg QID, both for 5 days, in a prospective, randomized, placebo-controlled, double-dummy...

  • Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis. Yoshida, Koichiro; Okimoto, Niro; Kishimoto, Michihiro; Fukano, Hiroshi; Hara, Hiroki; Yoneyama, Hirohide; Moriya, Osamu; Kawanishi, Masayoshi; Kimura, Makoto; Matsushima, Toshiharu; Niki, Yoshihito // Journal of Infection & Chemotherapy (Springer Science & Business;Oct2011, Vol. 17 Issue 5, p678 

    Moxifloxacin is a respiratory quinolone that is expected to be useful for treating community-acquired bacterial pneumonia, but few clinical studies and not a detailed evaluation of its pharmacokinetics have been conducted in Japan in patients with pneumonia. We assessed the efficacy and safety...

  • Development of a nanosomal formulation of moxifloxacin based on poly(butyl-2-cyanoacrylate). Shipulo, E.; Lyubimov, I.; Maksimenko, O.; Vanchugova, L.; Oganesyan, E.; Sveshnikov, P.; Biketov, S.; Severin, E.; Heifets, L.; Gel’perina, S. // Pharmaceutical Chemistry Journal;Mar2008, Vol. 42 Issue 3, p145 

    A nanosomal formulation of moxifloxacin has been prepared by anionic polymerization of poly(butyl-2-cyanoacrylate) in the presence of the drug. The poly(butyl-2-cyanoacrylate) nanoparticles absorb effectively moxifloxacin with a high total content and have a considerable capacity (> 45%). The...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics